Overview
- The Food and Drug Administration on Tuesday approved a modified-risk marketing claim for 20 Zyn nicotine-pouch products owned by Philip Morris, permitting statements that switching from cigarettes to those Zyn products lowers the risk of mouth cancer, heart disease, lung cancer, stroke, emphysema and chronic bronchitis.
- The products covered are specific flavors such as Cool Mint, Citrus, Coffee and Cinnamon offered in 3-milligram and 6-milligram nicotine strengths, while fruity flavors favored by youth were excluded from the authorization.
- The FDA emphasized that the authorization does not mean Zyn is safe, warned that nicotine pouches are not approved smoking-cessation aids, and said youth and nonusers should not start using them.
- As a condition of the approval, Swedish Match must run a five-year study of how customers perceive risks of the products, and the agency reserved the right to revoke the marketing claim if data show a significant rise in youth use.
- Public-health groups condemned the decision and called for reversal, and the move follows a broader shift in federal nicotine policy after 2024 that has opened pathways for smoke-free products to gain expanded marketing rights.